MDACC Study No:2007-0615 ( NCT No: NCT00658658)
Title:A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors
Principal Investigator:Cynthia E. Herzog
Treatment Agent:Panitumumab
Study Status:Open
Study Description:The goal of this research study is to find the highest tolerable dose of
panitumumab that can be given to children with solid tumors whose tumors have
come back or did not go away after earlier treatment(s).
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Bone; Brain; CNS; Eye; Kidney; Melanoma; Oropharynx; Ovary; Pediatrics; Phase I Studies; Sarcoma; Solid Tumors; Testis
Phase of Study:Phase I
Treatment Agents:Panitumumab
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Amgen, Inc.
Return Visit:Cohorts A or D: Weekly; Cohort B: q 2 weeks; Cohort C: q 3 weeks. All cohorts:
4 weeks after last treatment or more often if clinically necessary.
Home Care:None.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Cynthia E. Herzog
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults